Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma

Area of Science:

• Immunology
• Rheumatology
• Dermatology

Background:

• Diffuse scleroderma is a severe autoimmune condition with limited treatment options.
• Current therapies often have significant side effects and variable efficacy.

Purpose of the Study:

• To evaluate the safety and effectiveness of a treatment regimen involving anti-thymocyte globulin (ATG) followed by mycophenolate mofetil (MMF) for diffuse scleroderma.
• To assess the impact of this combination therapy on skin manifestations, functional status, and systemic disease progression.

Main Methods:

• A pilot study involving 13 patients with recent-onset diffuse scleroderma.
• Patients received a 5-day course of ATG, followed by 12 months of MMF.
• Outcomes measured included adverse events, skin scores, hand contractures, quality of life (EuroQol), functional assessments, pulmonary function, echocardiograms, and creatinine levels.

Main Results:

• A statistically significant decrease in mean scleroderma skin score from 28 to 17 after 12 months of MMF (P<0.01).
• Systemic disease markers remained stable, although hand contractures worsened.
• Five patients experienced serum sickness post-ATG, managed with corticosteroids; MMF was well-tolerated. One patient mortality occurred due to scleroderma renal crisis.

Conclusions:

• Anti-thymocyte globulin (ATG) and mycophenolate mofetil (MMF) demonstrate an acceptable safety profile in patients with diffuse scleroderma.
• The observed improvement in skin score and stabilization of systemic disease suggest potential therapeutic benefits.
• Controlled clinical trials are recommended to further validate the efficacy of ATG and MMF in diffuse scleroderma treatment.